CStone Pharmaceuticals (HKG:2616) said a patent was published for its internally developed antibody-drug conjugate (ADC) CS5006 on October 10, according to a filing with the Hong Kong bourse.
CS5006 is a new type of cancer drug designed to target a protein called integrin β4 (ITGB4), which combines with another protein, integrin α6 (ITGA6), to form a pair called α6β4. Using advanced technology and AI, researchers found that ITGB4 is common in cancers like lung, colon, esophageal, and head and neck cancers. This discovery suggests that targeting ITGB4 may be an effective way to treat these cancers.
The pharmaceutical company's shares were down nearly 3% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.